The Global Alzheimer's Platform (GAP) Foundation established a consortium of public and private stakeholders, including leading pharmaceutical companies, to develop the infrastructure to recruit participants for large scale Alzheimer's clinical trials. GAP's efforts also included establishing a global registry and a network of certified, high-performance clinical trial sites.
Our firm served as counsel on the development of the consortium.
